READ MORE - sgplus.se

885 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
885
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

READ MORE - sgplus.se

  1. 1. 1 CVs of selectedScientific Collaborators D A N I C A G R U J I C P H . D . | CELL (617) 599-3301 | HOM E (617) 427-7085 210 PARKER HILL AVENUE | BOSTON, MA 02120 dgrujic427@gmail.com P R O F I L E A Biopharmaceutical Scientist in a Senior Leadership position, with over 10 years of direct research management and provision of leadership to multiple projects focused on developing oral protein therapeutics for chronic gastrointestinal, metabolic and rare genetic disorders. She has an excellent understanding of all phases of pharmaceutical research and development, from methods and concepts of pharmacology, molecular and cell biology, protein chemistry and assay development. She provides leadership and critical process evaluation from initial phases of pre-clinical development, patent portfolio built up, IND filing, and subsequent process development leading from early research to Phase I clinical trials. She also supported late phase development and filing documents for NDA submission. She has led pre-clinical programs at two companies that have been transitioned successfully either to the public sector or acquired by other Pharmaceutical companies.  Developed and led pre-clinical programs for testing 5 oral drug candidatesfor gastrointestinal and metabolic disorders. Designed critical pre-clinical experiments in disease models to create supportfor NDA filingandnovel pediatricformulation  Identified and managed CRO’s for 3 independent programs within US, Europe and Asia, mostly focused for pre-clinical proof of concept work, but including large scale manufacturing of future drug candidates. Negotiatedtimelinesandbudgets.  Prepared and critically revised regulatory documents including reports for NDA, IND’s, IB’s and technical reports.  Conducted pre-clinical research program for gene therapy for diabetes and genetic disorders with CNSinvolvement(Lysosomal storage diseases).  Unique capabilities:  Demonstrates excellent organizational, communication and writing skills as evidenced by effective presentations at international meetings in US and Europe, with investment partners, external consultants, in the writing of scientific papers, technical reports, patent applications, and Federal and European regulatory documentation.  Works closely with the business development group in support of business alliance discussions and collaborations, serving as the lead in presentations to prospective partners and companies.  Recognized for initiative, enthusiastic attitude, excellent interpersonal, skills, and strong desire to solve challenging problems.
  2. 2. 2  Appreciated as someone who learns and transitions quickly and effectively as priorities change within company. E X P E R I E N C E ALNARA PHARMACEUTICAL, Cambridge , MA 2009- present Associate Director of Pharmacology  Leads design and implementation of critical pre-clinical studies with external collaborators to support NDA filing and testing of a novel pediatric formulation of Liprotamase [a non-porcine microbial-derived enzyme therapy for pancreatic insufficiency and related disorders]. Leads a research team that develops future drug candidate for hyperuricemia, gout, and kidney stones with European collaborators and US CROs. [most recently, testing of novel pediatric formulation of Liprotamase with European collaborators and CROs].  Performs budget planning within R&D group and negotiates budgets with CROs and external partners.  Works cross-functionally within the company to be the lead spokesperson for science that lends support to critical missions of Clinical and Business Development groups.  Identifies research partners and establishes external collaborations.  Integral part of the team that writes and reviews reports for NDA filing including pharmacology and clinical studies sections.  ALTUS PHARMACEUTICALS, MA 2004- 2009 Principal Scientist  Directs designs, plans, and performs pre-clinical proof of concept studies for treatment of hyperoxaluria and kidney stones, hyperuricemia and gout, and hyperphenylalanemia and PKU  Provided critical support to process development group by planning in details large scale protein production (800L) in E.coli and Pichia with CRO’s together with large scale in house protein purification and protein formulation using Altus proprietary technology.  Integral part of the team that prepared documentation for pre-IND and IND filling for the one of the early research programs; member of the team that had early conversation with FDA negotiating the requirements for the Phase I clinical trials.  Member of the team that executes toxicology studies for one of the programs prior Phase I safety trials  Works cross-functionally within the company to support Clinical Team for easy transfer from early phase of the research program to development stage and Phase I clinical trial, similarly supported Business Development group in developing partnership opportunities  Identified potential research partners and established external collaborations  Performs budget planning within R&D and negotiates budgets with CROs and external partners.  Prepares documents for regulatory and patent filings, 3 patent applications submitted within 2 years.  Prepares protocols, contracts,batch records for externalCRO’s; data reviewed and audited, first and corresponding author on manuscripts for publication and scientific presentations 
  3. 3. 3 TRANSKARYOTIC THERAPIES INC., Cambridge, MA 1999 – 2004 Senior Scientist  Directed design and implementation of future drug candidates, including biologics and small molecules Planned, organized and performed pre-clinical studies for gene therapy diabetes project; performed in vivo study using animal xenograft models and performed pharmacokinetic analysis  Directed and managed gene therapy diabetes project to a decision milestone  Member of a team responsible for the development of the pre-clinical program for the novel drug candidate for treatment of lysosomal storage diseases with CNS involvement, planed and set up in vitro experiments for protein delivery to the brain using novel technologies, analyzed data using new developed biochemical and immunology assays  Planned, organized and executed development of cell lines in mammalian cells, E.coli and Pichia pastoris for enzyme replacement therapy for rare metabolic disorders  Designed and managed proof of the concept experiments for the protein delivery to the specific organs implementing novel technologies (in vitro & in vivo)  Worked cross functionally in the company with Cell Development, Protein Purification and Animal Physiology groups as evidenced by the transfer technology, training individuals and project advancement fulfilling strict time lines  Organized and led several review presentations of R & D projects at companywide seminars, internal scientific forums and for senior management team  Worked closely with the business development group in support of business alliance  Supervised and trained 3-6 research scientists; effectively cascaded information from senior management team to the group BETH ISRAEL DEACONESS MEDICAL CENTER & HARVARD MEDICALSCHOOL, DIVISION OF ENDOCRINOLOGY AND METABOLISM, Boston, MA 1993 – 1999 Graduate and Post-Doctoral Scientist  Conducted research in the field of obesity and diabetes focus in development of mouse model using gene knockout and transgenic approaches  Developed mouse models which led to better understanding of the role of beta-3 and alpha 2 adrenergic receptors in the development of obesity and the potential of these genes to act as cellular targets for anti-obesity drugs in humans  Performed discovery work in the field of uncoupling proteins, related to the UCP2 and UCP3 genes, and their potential as anti-obesity drugs  Presented results at international meetings, department and hospital seminars, and video conferences with Eli Lilly  Supervised one research associate and taught molecular biology and physiology techniques to endocrine and post-doctoral fellows  Tested potential anti-obesity drug candidate in different mouse model for Eli Lily and Merck ARGONNE NATIONAL LABORATORY, Argonne, IL 1991 – 1993 BIOMEDICALAND MEDICALDEPARTMENT Visiting Scientist  Participated in the development of a novel high through put method for the Human Genome Sequencing Project called sequencing by hybridization (SBH)
  4. 4. 4  UsingSBH discoverednovel genesfrominfantbraincDNA and E. coli libraries  Workedon the identificationof carriersforthe Duchenne MuscularDystrophygene  Designedandperformedresearchrelatedtogene structure  Preparedmanuscriptsforpublicationandscientificpresentations T E C H N I C A L S K I L L S  Phase 1 clinical design and data analysis, pre-IND and IND and NDA documents writing ; design, execution , data analysis of the critical pre-clinical experiments necessary for either IND or NDA filling; pharmacokinetics and pharmacodynamics experiment design, Phase 1 clinical design and data analysis, development of cell-based models and assays,generation and characterization of transgenic and knockout animals  DNA modifying techniques, gene cloning, PCR,RT-PCR,PCR- based assays,Northern-,and Western –blotting, protein expression in mammalian, bacterial and yeast systems, E. coli and Pichia protein manufacturing at 800L scale, affinity protein purification, ELISA, RIA,tissue culture, in vivo and in vitro drug testing, sample analysis (biochemical, histochemical, immunologic)  E D U C A T I O N UNIVERSITY OF BELGRADE,YU Ph.D.,Molecular Biology and Physiology 1997 Research completed in Beth IsraelDeaconess MedicalCenter & Harvard Medical School M.S., Molecular Biology and Physiology 1988 B.S., Molecular Biology 1983 I N T E R N A T I O N A L M E E T I N G S 1. Submitted abstract to DDW 2010, NewOrleans,May 1-5, with the title “ Liprotamase, a microbial enzyme therapy, reverses impaired growth in pigs with exocrine pancreatic insufficiency (EPI)” was selected for oral presentation in the session Pancreatic Biology and Pathobiology. 2. Invited speaker to NIDDK Symposium 2008 “Anion Transporters and Oxalate Homeostasis: From Genes to Disease” December 8-9th ,2008, Rockville, MD with the title: “Oxalate Degrading Enzyme in Clinical Trials” 3. Invited speaker to 11th International Symposium on Urolithhisasi 2008,Nice,France,Sep 2-5, 2008 with two papers: “Oral therapy with ALTU-242 reduces hyperuricemia and hyperuricosuria in mice lacking urate oxidase (uox-/-) and “Hyperoxaluria regardless of Cause is Reduced and Nephrocalcinosis Prevented With Crystalline Oxalate Degrading Enzyme in Animal Model”. 4. Submitted abstract to ASN, Renal Week 2007,San Francisco,November 2007 with the title: “Oral therapy with crystalline oxalate degrading enzyme reduces hyperoxaluria in rodent models." was selected for 7 min oral presentation in the Other Mundelian Syndromes session. 5. Submitted abstract to 2007 AUA Annual Meeting,Anaheim, May 2007 with the title: Oral therapy with crystalline formulation of oxalate degrading enzyme in rodent models with hyperoxaluria” was selected for 5 min oral presentation at Stone Disease: Research session,and was awarded as a Best poster. 6. Invited speaker at The BONE, STONEand the KIDNEY Satellite Symposium,Post-Congress Official Satellite Symposium of World Congress of Nephrology (WCN 07),Angra dos Reis,Rio de Janeiro, April 2007 with the paper: “Oxalate degrading enzymes in the treatment of primary hyperoxaluria”
  5. 5. 5 7. Invited speaker at annual meeting of ASN, Renal Week 2006,San Diego, November 2006 at Bone/Stone session with the paper: “Crystalline formulation of an orally administered oxalate degrading enzyme reduces hyperoxaluria in mouse genetic model”. P U B L I C A T I O N S 1. Grujic D, Salido EC, Shenoy BC, Langman, CB, McGrath M, Patel RJ, Rashid A, Mandapati S, JungC,and Margolin AL: Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme inmice withhyperoxaluria (AJN,epub Aug,2008) 2. Boucher J, Castan-Laurell I, Le Lay S, Grujic D, Sibrac D, Krief S, Lafontan M, Lowell, B B, Dugaill I, Saulinier-Blache, J S, Valet, P: Human alpha 2A-adrenergic receptor gene expressed in transgenic mouse adipose tissue under the control of its regulatory elements. J Mol Endocrinology 2002 Oct:29(2):251-6 3. Visentin V, Morin N, Fontana E, Prevot D, Boucher J, Castan I, Valet P, Grujic D, Carpene C: Dual action of octopamine on glucose transportinto adipocytes:inhibition via beta2-adenoreceptor activation and stimulationviaoxidationbyamine oxidases. JPharmacolExp Ther.2001 Oct 299 (1):96-104 4. Zhang Cy, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vida-Puig A J, Boss O, Kim Y B, Zheng X X, Wheeler M B, Shulman G I, Chan C B, Lowell B B: Uncoupling protein-2 negatively regulates insulin secretion and is major link between obesity, beta cell dysfunction and type 2 diabetes. Cell 2001 Jun 15; 105(6):745-55 5. Grujic D, Valet P, Wade J, Ito M, Zingaretti M.C, Soloveva V, Ross S.R, Graves R.A, Cinti S, Lafontan M, Lowell B.B: Expression of human alpha 2-adrenergic receptors in adipose tissue of beta 3- adrenergic receptor-deficient mice promotes diet-induced obesity. J. Biol. Chem. 2000 Nov 3; 275 (44): 34797-802 6. Vidal-Puig A J, Grujic D, Zhang C.Y, Hagen T, Boss O, Ido Y, Szczepanik , A, Wade J, Mootha V, Cortright R, Muoio D M, Lowell B B: Energy metabolism in uncoupling protein 3 gene knockout mice. J. Biol. Chem.2000 May 26; 275 (21): 6258-66 7. Cortright, R, Zheng, D, Jones, J P, Fluckey, J D, DiCarlo, S E, Grujic, D, Lowell, B B and Dohm, G L: Regulation of skeletal muscle UCP-2 and UCP-3 gene expression by exercise and denervation. Am. J. Physiol. (1999) vol 276 (1 Pt):E 217-21 8. Fletcher, D S, Candelore M R, Grujic, D, Lowell, B B, Luell, S, Susulic, S V, Macintyre, D E: Beta-3 adrenergic receptor agonist cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor. J. Pharm. Experim. Therap. (1998) vol. 287, No 2, p 720-724 9. Boyer, B, Barnes, B M, Lowell, B B and Grujic, D: Differential regulation of uncoupling protein gene homologues in multiple tissues of hibernating ground squirrels. Am. J. Physiol. (1998): 275 (RegulatoryIntegrative Comp.Physiol. (44) R1232-1238
  6. 6. 6 10. Ito, M, Grujic, D, Abel, E D, Vidal-Puig, A, Susulic, V S, Lawitts, J, Harper, M-E, Himms-Hagen, J, Strosberg, A D and Lowell, B B: Mice expressing human but not murine b3-adrenergic receptors underthe control of humangene regulatoryelements. Diabetes (1998) Sep47(9)1464-1470 11. Solanes, G, Vidal-Puig A, Grujic D, Flier J S, Lowell B B: The human uncoupling protein-3 gene. Genomic structure, chromosomal location and genetic basis for short and long transcripts. J Biol Chem 1997 Oct 10; 272(41) 25433-6 12. Grujic, D, Susulic, S V, Harper, M-E, Himms-Hagen, J, Cunningham, B, Corkey, B and Lowell B: b3- Adrenergic receptors on white and brown adipocytes mediate b3-selective agonist-induced effects on energy expenditure, insulin secretion and food intake. J. Biol. Chem. (1997) Jul11; 272 (28), 17686-17693 13. Grujic, D, Vidal-Puig, A, Solanes, G, Flier, J S, and Lowell: B B, UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem. Biophys.Res.Commun. (1997) 235:79-82 14. Solanes, G, C-Y. Zang, S-Susulic, V, Grujic, D, Hollenberg, T, Chung, W K, Leibel, R, and Lowell, B B: Transgenic assessment of leptin gene transcription and characterization of the ob2j mutation. Diabetes(1997) 46:59A 15. Milosavljevic, A, Zeremski, M, Strezoska, Z, Grujic, D, Dyanov, H, Batus, S, Salbego D, Paunesku, T, Soares, M B, and Crkvenjakov, R: Discovering distinct genes represented in 29,579 clones from infant brain cDNA libraries by applying sequencing by hybridization methodology. Genome Research (1996), 6, p132-141 16. Milosavljevic, A, Savkovic, S, Crkvenjakov, R, Salbego, D, Serrato, H, Kreuzer, H, Gemmell, A, Batus, S, Grujic, D, Carnahan, S, Paunesku, T and Tepavcevic, J: DNA sequence recognition byhybridization to short oligomers: experimental verification of the method on the E.coli. genome. Genomics (1996), 37 (1),77-86 17. Milosavljevic, A, Strezoska, Z., Zeremski, M., Grujic, D., Paunesku,T., Crkvenjakov, R. Clone: clustering by hybridization. Genomics (1995), 27 (1) p 83-9 18. Grujic, D., Strezoska, Z, and Crkvenjakov, R, High: throughput PCR procedure for up to 6-kb lengths of DNA. Biotechniques (1994), 17, 291-294 19. McClathey, A, Trofatter, J, Mckenna-Yasek, D, Raskind, W, Bird, T, Vance, M, Gilchrist, J, Hausmanowa-Petrusewicz, I, Arahata, K, Radosavljevic (Grujic), D, Haines, J, Gusella, J F and Brown, R H, Dinucleotide: repeat polymorphisms at the SCN4A locus suggest allelic heterogenity of both hyperleucemic periodic paralysis and paramiotonicongenita. American Journal of Human Genetics, (1992), 50, 896-901
  7. 7. 7 20. Strezoska, Z, Paunesku, T, Radosavljevic (Grujic) D, Labat, I, Drmanac, R and Crkvenjakov R, DNA sequencing by hybridization: 100 bases read by a non-gel based method. Proc. Nat. Acad. Sci, USA, (1991), 88, p 0089-10093 21. Radosavljevic (Grujic), D, Todorovic, D and Crkvenjakov R, Deletion analysis of Duchenne Muscular DystrophyusingcDNA probesandmultiplexPCR. Neurologica Croatica, (1991),40, 157-164 22. Radosavljevic (Grujic), D, Todorovic, D and Crkvenjakov, R: Analysis of chromosomal deletions in DMD patients using multiplex PCR and cDNA probes. Journal of Neurological Science (1990), Supplementtovol.98 23. Stevanovic, M, Paunesku, T, Radosavljevic (Grujic), D, Drmanac R and Crkvenjakov R: Variant chromosomal arrangementof adultbetaglobin genesinrat. Gene, 79 (1989), 139-150 24. Radosavljevic (Grujic), D and Crkvenjakov, R: Genome sequence of rat beta-globin major gene. Nucleic Acids Research, (1989), 17, 4368
  8. 8. 8 Björn R Weström, Prof 1. Personal data Full name: Björn Ragnar WESTRÖM Place and date of birth: Lycksele, Sweden, 8 May 1950 Home address: Doktorsgatan 9C, SE-262 52 Ängelholm, Sweden Phone; +46 (0)431 18622 Current work address: Department of Cell and Organism Biology, Animal Physiology, Lund University, Helgonavägen 3B, S-223 62 Lund, Sweden Phone; +46 (0)46 2229733, Fax; +46 (0)46 222453 E-mail; Bjorn.Westrom@cob.lu.se Nationality: Swedish 2. Academic exams and qualifications 2001 Professor in Zoophysiology, Lund University 1987 Associate Professor in Zoophysiology (Docentkompetens), Lund University 1985 Doctor of Philosophy (Ph.D) in Zoophysiology, Lund University. Thesis title; Proteinase inhibitors in mammalian blood serum and mammary secretions with special reference to their function in the growing pig, 1981. (Supervisor Börje Karlsson) 1974 Advanced course in Zoophysiology (D2-level, corresp. to exam work), Lund University (0.5 year) 1974 Bachelor of Science (B.Sc) in Chemistry and Biology, Lund University (3 years) 3. Employments 0106-ongoing Professor in Zoophysiology, Dept Cell and Organism Biology, Lund University (with 50 % research/50 % teaching) 8910-0105 Senior lecturer in Zoophysiology, Dept Animal Physiology, Lund University 8807-8910 Senior researcher, Dept Animal Physiology, Lund University
  9. 9. 9 8207-8806 Postdoctoral fellow, Dept Animal Physiology, Lund University, financed by the Swedish Natural Science Research Council (NFR) 8107-8206 Assistant, 50%, Dept Animal Physiology, Lund University 8007-8206 Postdoctoral fellow, 50%, Dept Animal Physiology, Lund University 7907-8106 Assistant, 50%, Dept Biology, Lund University 4. Membership in scientific societies 2008 Royal Physiografic Society in Lund 5. Grants 2001-03 The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS), Functional development of the digestive system and its impact on growth of young farm animals. B. Weström, Rådberg, Evilevitch, (516 kSEK/year). 2002–05 The Swedish Agency for Innovation Systems (Vinnova). Lectins and glutamine derivates improve health around weaning. B. Weström (Total 500 kSEK) 2007–08 Antidiabetic Food Centre/Vinnova. Blood pressure reducing effects of different fermented plant materials using an animal model. B. Weström (Total 419 kSEK) 6. Academic duties PhD :Esbjörn Telemo (1986); Bertil Ohlsson (1987); Cynthia de Wit (1987); Gunilla Ekström (1990); Stefan Pierzynowski (1991); Hans Folkesson (1992); Per Michanek (1994); Niclas Pantzar (1995); Quan Wang (1995); Mary-Jane Thaela (1997); Pål Lundin (1997); Dan Rantzer (1997); Pernilla Nejdfors (2000); Klas Rådberg (2001); Lotta Georgsson (2002); Lena Evilevitch (2004); Ann Linderoth (2006); Shahram Lavasani (2006); Frida Fåk (2008); Annica Thomsson ; Olena Prykhodko (2008); Sofia Rengman (2009); Olexandr Fedkiv (2009). Teaching at basic and advanced courses for natural science students:  Lectures in basic Immunology (MOBA01, KLGN01)(1987-ongoing).  Lectures and examination in basic Zoophysiology (BIOC01, BIMM) (1992-ongoing).  Course leadership, lectures, practicals and examination and in advanced Immunology (BIOR16), 15 credits (1987-ongoing, each semester).  Initiative to and planning, course leadership, lectures and examination in Nutrition Physiology (BIOR50), 15 credits (2005-ongoing ).  Supervision of 22 research projects (4 credits) within the advanced course in Zoophysiology (1977-ongoing).  Supervision and examination of about 100 projects for master candidates in Immunology and Zoophysiology 15-30 credits (1976-ongoing).
  10. 10. 10 Adrian Paul HARRISON, Ass Prof Thorvaldsensvej 19, 2.th, 1871 Frederiksberg C. Details: Born November 26th 1965, North Ferriby, Yorkshire, England. British by birth. Danish married since May 1995. E-mail: adh@life.ku.dk Phone: 00 45 35 33 25 68 Fax: 00 45 35 33 25 25 Training/Education: 1985-88 HND - Higher National Diploma: Credit (Agric.), Harper Adams College, Shrops- hire, England. 1988-91 BSc - Bachelor of Science: Hons. (2:1) (Agric. Biochem. & Nutr.), University of Newcastle Upon Tyne, England. 1991-94 D.Phil. - Doctor of Philosophy, University of Cambridge, England. Regulation of porcine skeletal muscle growth and differentiation, submitted Sept 1994, examined Feb 1995 and admitted to the Degree Nov 1995. Appointments: 1991-94 Awarded a BBSRC Research Studentship, Department of Cellular Physiology, The Babraham Institute, Babraham, Cambridge, CB2 4AT, England. 1994-99 Research Scientist (Forskningsadjunkt), Department of Physiology, Faculty of Medicine, University of Aarhus, DK-8000 Århus C, Denmark. 1999-2001 Research Scientist (Forskningsadjunkt), Department of Anatomy & Physiology, The Royal Veterinary & Agricultural University (KVL), Grønnegaardsvej 7, DK-1870 Frederiksberg C, Denmark. 2001- Associate Professor, Dept. of Animal and Veterinary Basic Sciences, Copenhagen University, Faculty of Life Sciences (LIFE CU), Grønnegaardsvej 7, DK-1870 Frederiksberg C, Denmark.
  11. 11. 11 Qualifications: 2007 Professor: Judged, by an International Committee, as being qualified at the Professor level - Copenhagen University, Faculty of Life Sciences. Scientific The Nutrition Society, August 1994 Southampton meeting, student Merits prize for the best oral presentation out of 135 entries. Fellowships: Awarded an Alfred Benzon Investigator Fellowship (1997 and 1998). Associate Editor: Journal of Pre-Clinical & Clinical Research. The Open Bone Journal Languages: Fluent in Danish – verbal and written. Can understand Norwegian and Swedish – spoken and written language. Panels: Advisory Panel: EU COST Action 925: The importance of prenatal events for postnatal muscle growth in relation to the quality of muscle based foods Scientific Panel Member: Research School for Animal Production and Health - RAPH Funding: 2002 – 1.200.000 kr RAPH – Nutrition and reproduction in harmony – Project Leader 2003 – 1.547.000 kr BRFP II – Understanding the language of muscle Project Leader 2008 – 1.547.000 kr RAPH – Alpha-ketoglutarate and collagen for healthy livestock production - Project Leader 2009 – 100.000 $ - Rhodimet Funded Project – Methionine and muscle
  12. 12. 12 function – Co-Project Leader Teaching: Coordinator: 1) 260013 Production Anatomy & Physiology (50 to 70 students), LIFE, CU Lecturer: 1) 300047 Veterinary Basic Physiology, LIFE, CU 2) 260008 Experimental Animal Nutrition & Physiology, LIFE, CU 3) Basic Animal Production & Nutrition, LIFE, CU 4) Thematic Course: Animal Science, LIFE, CU 5) B3 F09-UE Meat production, LIFE, CU 6) Bio 651 Nutrition Physiology: Guest Lecturer in the Dept. of Zoophysiology at Lund University, Sweden. 7) MSc/Postgraduate Diploma in Applied Toxicology: Guest Lecturer for the Safety Pharmacology Module – University of Surrey, UK Referee for: Acta Physiol Scand; American Journal of Physiology; Muscle & Nerve; Journal of Applied Physiol.; Zoomorphology; Acta Veterinaria Scandinavica; Journal of Pharmacology & Toxicology; J.Comparative Biochemistry & Physiology; Livestock Science; J. of Clinical Nutrition; International Journal for Vitamin & Nutrition Research; British Medical Journal; Environmental Science & Pollution Research. Guest Speaker: Safety Pharmacology Society Meeting (3rd), Noordwijk aan Zee, The Netherlands. “Gastrointestinal tract: Models and techniques for use in safety pharmacology” 2003. Safety Pharmacology Society Meeting (7th),Edinburgh, Scotland. “Gastrointestinal studies” 2007. British Museum – Gallery Talk – Feb 2009 – ”Olympic Victor´s Dark Ointment” for the Wellcome Institute. Researchlinks: Dr. Inge Eidemak, Nephrology Dept. RigsHospitalet, Denmark (Renal failure & muscle weakness project); Prof. Stefan Pierzynowski, Cell Biology Dept. Lund University, Sweden (Intestinal physiology); Dr. Margrethe Therkildsen, Meat Science Section, DJF, Tjele, Denmark (Meat quality); Dr. Lennart Friis-Hansen, MD, Dr Med Sci. Dept. of Clinical Biochemistry kb3011, RigsHospitalet, Denmark.
  13. 13. 13 Wojciech Rzeski, Prof Place and date of birth (d/m/y): Szubin, Poland; 12-04-1963 Nationality: polish Address: Biskupińska 56, 20-830 Lublin, Poland 1. Working experience 1.1 Actual and previous positions  2010 – continuum, Professor, Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland  2010 – continuum, Docent, Department of Medical Biology, Institute of Agricultural Medicine, Lublin, Poland  2006-2009, Docent, Department of Toxicology, Institute of Agricultural Medicine, Lublin, Poland  2005-2006, Adiunkt, Department of Toxicology, Institute of Agricultural Medicine, Lublin, Poland  1997-1999, Researcher, Department of Pediatric Neurology, Humboldt University, Berlin, Germany 2. Education and training 2. 1 Degrees and evaluation of qualification  Associated Professor, Biological Sciences, Faculty of Biology and Earth Sciences, Maria Curie-Skłodowska University, Lublin, Poland, 2005  Ph.D, Biological Sciences, Faculty of Biology and Earth Sciences, Maria Curie- Skłodowska University, Lublin, Poland, 1995  MSc, Microbiology, Faculty of Biology and Earth Sciences, Maria Curie- Skłodowska University, Lublin, Poland, 1987 2.2 Other education  Pedagogic - methods, Maria Curie-Skłodowska University, Lublin, Poland  European Workshop and Postgraduate Training Course UNESCO-ROSTE in Modern Biotechnology, Czechoslovak Academy of Sciences, Prague, Czechoslovakia  Biobiz™ Training Workshop, Commercialization of Life Sciences Research
  14. 14. 14 3. Scientific qualifications 3.1 Scientific production / List of the publication (in total 178 publications) 3.1.1 Articles published in scientific journals – peer- review papers (2001 – 2010) 1. Rzeski W., Turski L., Ikonomidou C. (2001): Glutamate antagonists limit tumor growth. Proc. Natl. Acad. Sci. USA 98, (11), 6372-77. 2. Rzeski W., Paduch R., Klatka J., Kandefer-Szerszeń M., Stepulak A., Pożarowski P, Zdzisińska B. (2002): Establishment and preliminary characterization of the two cell lines derived from larynx carcinoma. Folia Histochem. Cytobiol., 40, 195-196. 3. Rzeski W., Ikonomidou C., Turski L. (2002): Glutamate antagonists limit tumor growth. Biochem. Pharmacol. 64, 8, 1195-1200. 4. Tchórzewski M., Krokowski D., Rzeski W., Issinger O-G., Grankowski N. (2003): The subcellular distribution of the human ribosomal „stalk” components: P1, P2 and P0 proteins. Int. J. Bioch.Cell Biol., 35, 203-211. 5. Hansen H.H., Briem T., Dzietko M., Sifringer M., Voss A., Rzeski W., Zdzisinska B., Thor F., Heumann R., Stepulak A., Bittigau P., Ikoonomidou C. (2004): Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing brain. Neurobiol. Dis., 16, 440-453. 6. Rzeski W., Pruskil S., Macke A., Felderhoff-Mueser U., Reiher A.K., Hoerster F., Jansma C., Jarosz B., Stefovska V., Bittigau P., Ikonomidou C. (2004): Anticancer agents are potent neurotoxins in vitro and in vivo. Ann. Neurol., 56, (3), 351-360. 7. Rzeski W., Turski L., Ikonomidou C. (2005): Anticancer effects of glutamate antagonists. W: Gill S. and Pulido O. (red). Glutamate receptors in peripheral tissue: Excitatory transmission outside the CNS. Kluwer Academic/Plenum Publishers, New York, USA, 4, 77-85. 8. Ginalska G., Osinska M., Uryniak A., Urbanik-Sypniewska T., Belcarz A., Rzeski W., Wolski A. (2005): Antimicrobial activity of gentamycin-bonded gelatin-sealed polyterephthalate ethylene vascular prostheses. Eur. J. Vasc. Endovasc. Surg., 29, 419- 424. 9. Rzeski W., Kocki T., Dybel A., Wejksza K., Zdzisińska B., Kandefer-Szerszeń M., Turski W.A., Okuno E., Albrecht J. (2005): Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons. J. Neurosci. Res., 80, 677-682. 10. Wejksza K., Rzeski W., Okuno E., Kandefer-Szerszen M., Albrecht J., Turski W.A. (2005): Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in OLN-93 oligodendrocyte cell line. Neurochem. Res., 30, (8), 963-968. 11. Stepulak A., Sifringer M., Rzeski W., Endesfelder S., Gratopp A., Pohl E., Bittigau P., Felderhoff-Mueser U., Kaindl A.M., Bücher C., Hansen H.H., Stryjecka-Zimmer M., Turski L., Ikonomidou C. (2005): NMDA antagonist inhibits the extracellular signal- regulated kinase pathway and suppresses cancer growth. Proc. Natl. Acad. Sci. USA, 102, (43), 15605-15610. 12. Parada-Turska J., Rzeski W., Zgrajka W., Majdan M., Kandefer-Szerszeń M., Turski W.A. (2006): Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid inhibits proliferation of synoviocytes in vitro. Rheumatol. Int., 26 (5), 422-426. 13. Wejksza K., Rzeski W., Turski W.A., Hilgier W., Dybel A., Albrecht J. (2006): Amonia at pathophysiologically relevant concentrations activates kynurenic acid synthesis in cultured astrocytes and neurons. Neurotoxicology, 27, (4), 615-618.
  15. 15. 15 14. Parada-Turska J., Rzeski W., Majdan M., Kandefer-Szerszeń M.,Turski W. (2006): Effect of glutamate antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. Eur. J. Pharmacol., 535, (1-3), 95-97. 15. Kuc D., Rahnama M., Tomaszewski T., Rzeski W., Wejksza K., Urbanik-Sypniewska T., Parada-Turska J., Wielosz M., Turski W.A. (2006): Does kynurenic acid naturally occurring in human saliva influence oral microflora? Parmacol. Rep., 58, (3), 393-398. 16. Rzeski W., Stepulak A., Szymański M., Sifringer M., Kaczor J., Wejksza K., Zdzisińska B., Kandefer-Szerszeń M. (2006): Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedeberg’s Arch. Pharmacol., 374, 11-20. 17. Rzeski W., Matysiak J., Kandefer-Szerszeń M. (2007): Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound. Bioorg. Med. Chem., 15, (9), 3201-3207. 18. Parada-Turska J., Paduch R., Majdan M., Kandefer-Szerszeń M., Rzeski W. (2007): Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol. Rep., 59, (2), 233-237. MNiSW – 19. Stepulak A., Sifringer M., Rzeski W., Brocke K., Gratopp A., Pohl E.E., Turski L., Ikonomidou C. (2007): AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol. Ther., 6 (12), 1908-1915. 20. Jakubowicz-Gil J., Rzeski W., Zdzisińska B., Dobrowolski P., Gawron A. (2008): Cell death and neuronal arborization upon quercetin treatment in rat neurons. Acta Neurobiol. Exp. (Wars), 68, (2), 139-146. 21. Parada-Turska J., Mitura A., Brzana W., Jabłoński M., Majdan M., Rzeski W. (2008): Parthenolide inhibits proliferation of fibroblast-like synoviocytes in vitro. Inflammation, 31 (4), 281-285. 22. Juszczak M., Matysiak J., Brzana W., Niewiadomy A., Rzeski W. (2008): Evaluation of antiproliferative activity of 2-(monohalogenphenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4 thiadiazoles. ArzneimForsch/DrugRes., 58, (7), 353-357. 23. Stepulak A., Rzeski W., Sifringer M., Gratopp A., Kupisz K., Turski L., Ikonomidou C. (2008): Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol. Ther., 7 (10), 1685 – 1693. 24. Jakubowicz-Gil J., Rzeski W., Zdzisinska B., Piersiak T., Weiksza K., Glowniak K., Gawron A (2008) Different sensitivity of neurons and neuroblastoma cells to quercetin treatment. Acta Neurobiol. Exp. (Wars) 68 (4), 463-476. 25. Belcarz A., Ginalska G., Zalewska J., Rzeski W., Slosarczyk A., Kowalczuk D., Godlewski P., Niedzwiadek J. (2008): Covalent coating of hydroxyapatite by keratin stabilizes gentamicin release. J. Biomed. Mater. Res. Part B: Appl. Biomater. 89B, (1), 102-113. 26. Paduch R., Rzeski W., Klatka J. (2009): The effect of cisplatin on human larynx carcinoma cell motility. Folia Histochem. Cytobiol., 47, (1), 75-79. 27. Wejksza K., Rzeski W., Turski W.A. (2009): Protective effects of kynurenic acid against homocysteine induced impairment of endothelial cell function. In vitro study. Pharmacol. Rep., 61 (4), 541-546. 28. Stepulak A., Luksch H., Gebhardt C., Uckerman O., Sifringer M., Rzeski W., Turski L., Ikonomidou C. (2009): Expression of glutamate receptors in cancer cell lines. Histochem. Cell Biol., 132 (4), 435-45. 29. Rzeski W., Stepulak A., Szymański M., Juszczak M., Grabarska A., Sifringer M., Kaczor J., Kandefer-Szerszeń M. (2009): Betulin elicits anticancer effects in tumor primary cultures and cell lines In vitro. Basic Clin. Pharmacol. Toxicol., 105 (6), 425-432. 30. Lemieszek M.K., Langner E., Kaczor J., Kandefer-Szerszeń M., Sanecka B., Mazurkiewicz W., Rzeski W. (2009): Anticancer effect of fraction isolated from medicinal
  16. 16. 16 birch polypore mushroom, Piptoporus betulinus (Bull.: Fr.) P. Karst. (Aphyllophoromycetideae): in vitro studies. Int. J. Med. Mushrooms, 11 (4), 351-364. 31. Jakubowicz-Gil J., Langner E., Wertel I., Rzeski W. (2010): Temodal, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem. Biol. Interact., 188 (1):190-203. 3.2 Scientific leadership  Evaluation of anticancer activity of New aminothiadiazole derivatives ,grant no N N401 223734, Ministry of Science and Higher Education, 2008-2011  Anticancer activity of alfa-ketoglutarate, Essentys, Sweden  Anticancer activity of heated potato fibre Potex, Essentys, Sweden  Kynurenic acid in brain and periphery – its role in physiology and pathology, Foundation for Polish Science, Mistrz Programme (Prof. Waldemar Turski), 2008-2011
  17. 17. 17 Olena Prykhod'ko, PhD Date of birth 1979-06-29 Nationality Ukrainian Marital Status Married Children Two sons (born 2006 and 2008) Languages Ukrainian, Russian, English, Swedish Hobby Photographing, glass bead weaving Contact: +46 46 730488609 e-mail: prykhodko_olena@hotmail.com Kämnärsvägen 3A:120 SE-226 46 Lund Sweden
  18. 18. 18 UNIVERSITY EDUCATION: 2005-2008, PhD (Zoological Cell Biology) Department of Cell and Organism Biology, Lund University, Sweden 2000-2001, MSc (Biochemistry) (with honours) Department of Biochemistry and Biophysics, Dnepropetrovsk National University, Ukraine 1996-2000, BSc (Biology) (with honours) Dnepropetrovsk National University, Dnepropetrovsk, Ukraine RESEARCH EXPERIENCES May 2009 - present Research projects 2009-2010: - Role of the immune system in gut development of young mammals. - Role of pancreatic enzymes in gut development and small intestinal mucosal function 2005-2008 PhD studies with 15% of teaching duties (Dept of Cell and Organism Biology, Lund University, Sweden) Theses: “Involvement of the immune system in phytohaemagglutinin-induced structural and functional precocious maturation of the gut in young rats.” Supervisors: Prof. B. Weström, Prof. S. Pierzynowski Faculty opponent: Prof. E. Telemo, Dept of Rheumatology and Inflammation Research, University of Gothenburg, Sweden 2004-2005 Research project in animal physiology (Dept of Cell and Organism Biology Lund University, Sweden) - Effect of exposure to the lectin, phythohaemagglutinin (PHA), on gut of young suckling rat. Supervisors: Prof. B. Weström, Prof. S. Pierzynowski 2002-2003
  19. 19. 19 Postgraduate practice in inflammatory research (Dept of Medical Microbiology, Dermatology & Infection (MMDI), Lund University, Sweden) - Inflammation and regulation of adhesion molecules expressing in gastric and biliary epithelial cell-lines after bacterial infection with Helicobacter spp. Implication of molecular techniques. Supervisors: Prof. T. Wädstrom, Ass Prof. Å. Ljungh 2000-2001 Graduate research (diploma work) (Dept of Biochemistry and Biophysics, Dnepropetrovsk National University, Ukraine) - The influence of acute and chronic ionizing irradiation on the epithelial proliferation and calcitonin expression in C-cells of thyroid gland in rats. Implication of histological and immune methods. Supervisors: Prof. G. Ushakova, PhD. I. Kornilovska. TEACHING DUTIES 2005- present - Lab assistant (Nutritional physiology BIOR50, Immunology BIOR16) at Lund University - Supervision of Project- and Master-students (Olof Torper Ht 2006, Jennifer Pieper Vt 2007, Lidia Kopacz Vt 2007, Bo Lindberg Ht 2007, Krister Andersson Vt2009, Hamid Bashar Vt2010) PROFESSIONAL EMPLOYMENT May 2009 - present Researcher at Lund University, Dept of Biology (Sölvegatan 35 C, SE 223 62 Lund, Tel: +46 46 2229732, E-mail: Olena.Prykhodko@cob.lu.se) Oct 2009 – June 2010 Scientist in vivo, project assistant, Probi AB (Ideon Gamma 1, Sölvegatan 41, SE - 223 70 Lund, Sweden) 2001-2002 Laboratory assistant, research worker, at Morphological laboratory "BIONTEC" collaborating with Center of Molecular Physiology, National Academy of Science, Dnepropetrovsk, Ukraine. Clinical research, establishing of diagnostic techniques:
  20. 20. 20 OTHER ACTIVITIES: Reviewer in peer-reviewed journals: Livestock Science (2), Pharmacological Research (1). Participant in congresses and conferences. GRANTS AND AWARDS: Participant in Visby program 2004 supported by Swedish Institute. Personal grants supported by Kgl. Fysiografiska Sällskapet i Lund and Dir A. Påhlssons Stift by more than 200 000 SEK for running projects. Bibliography been invited for publishing in Marquis Who's Who in the World. PATENTS AND PUBLICATIONS 1 patent, 7 articles in peer-reviewed journals. RELEVANT TECHNICHAL SKILLS - Scientist in vivo (rodents, ungulates), i.e., stomach-tube feeding, s.c., i.p., i.v. injections, behaviour test, blood pressure (CODA 2 system) ect. - Anaesthesia, euthanasia, obduction, blood/tissue/organs sampling, fixation - Histological technique (cryo and paraffin sections) - Immune cell isolation (blood, lymphoid tissue) - Histological staining methods: Hematoxylin-Eosin, May-Grunwald – Giemsa. - Immunohistochemistry and immunofluorescent analysis - Tissue morphometry (ImageJ, ImagePro software) - Enzyme-linked immunosorbent assay (ELISA) - Agarose electrophoresis, immunoassays - Statistics

×